We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer.
Introduction
It is estimated that prostate cancer was the second most frequently diagnosed cancer in the USA in 2008, and that it caused more than 28,000 deaths [1] . Despite recent advances in the detection, diagnosis, and treatment of prostate cancer, there is a need for more effective therapies. Unfortunately, most conventional therapeutic modalities, such as androgen ablation therapy, frequently result in androgen-independent cancers. These cancers are typically more aggressive, metastatic, and resistant to chemotherapeutic agents than androgen-dependent prostate cancer [2] [3] [4] . Therefore, agents that are effective against both androgen-sensitive and androgen-independent prostate cancers, and against genotypically diverse cancers are critically needed.
In search of alternative therapeutic compounds, many scientists have turned to the subterranean marine environment. Natural products extracted from marine invertebrate animals (and synthetic derivatives of these products) have proven to be extraordinary resources for biologically active compounds [5] [6] [7] [8] . In particular, marine sponges have proven to be an exceptionally abundant source of chemically and biologically diverse natural products [9] [10] [11] [12] .
As part of our ongoing interest in the potential therapeutic benefits of marine natural products (and in a search for less toxic analogs to conventional compounds), we recently developed a schematic for the organic synthesis of makaluvamine analogs. A number of synthetic pyrroloiminoquinone makaluvamine alkaloids with proven anticancer activities possess substitutions at the 7-position of the pyrroloiminoquinone ring. Therefore, we explored substitutions of increased steric bulk, hydrophobicity, and hydrophilicity at the 7-position of the pyrroloiminoquinone ring [13, 14] . Various synthetic makaluvamine derivatives were tested against a panel of cancer cell lines, and the 4 fluorobenzyl substituted analog (FBA-TPQ) exhibited excellent cytotoxicity in the low micromolar range against a variety of human cancer cells, including prostate cancer cells [15] .
While FBA-TPQ (Fig. 1a) exhibited excellent growth inhibition against the cancer lines, the mechanisms of action responsible for these effects are largely unknown. To investigate the possible mechanisms governing the cytotoxic activity of FBA-TPQ, we employed LNCaP, PC3 and TRAMP C1 human and murine cancer cell lines as models of prostate cancer.
Materials and methods

Chemicals and reagents
All chemicals and solvents were of the highest analytical grade available. The anti-human MDM2 (SMP14) and Bax FBA-TPQ was synthesized using methods reported previously [15] . The purity of the compound was greater than 99.0%, based on 1 H-NMR, 13 C-NMR, and mass spectral analyses. The data for the compound is given below. Cell survival/viability assay
Spectral data
The effect of FBA-TPQ on human cancer cell growth, expressed as the percentage of cell survival, was determined using the MTT assay. The cells were grown in 96-well plates at 4-5×10 3 cells per well and exposed to the test compound (0, 0.1, 0.5, 1, 2.5 and 5 µM). After incubation for 72 hr, 10 µL of the MTT solution (5 mg/mL; Sigma; St. Louis, MO) were added into each well. The plates were incubated for 2-4 hr at 37°C. The supernatant was then removed and the formazan crystals were dissolved with 100 µL of DMSO. The absorbance at 570 nm was recorded using an OPTImax microplate reader (Molecular Devices; Sunnyvale, CA). The cell survival percentages were calculated by dividing the mean OD of compoundcontaining wells by that of control wells.
Cell proliferation assay
Bromodeoxyuridine (BrdUrd) incorporation (Oncogene, La Jolla, CA) was employed to determine the effect of the test compound on cell proliferation. Cells were seeded in 96-well plates (8×10 3 to 1.2×10 4 cells per well) and incubated with various concentrations of FBA-TPQ (0, 0.1, 0.5, 0.75, or 1.0 µM) for 24 hr. BrdUrd was added to the medium 10 hr before termination of the experiment. The extent of BrdUrd incorporation into cells was determined with an anti-BrdUrd antibody, and absorbance was measured at dual wavelengths of 450/540 nm with an OPTImax microplate reader (Molecular Devices; Sunnyvale, CA).
Cell cycle measurements
To determine the effects of the test compound on the cell cycle, cells (2-3×10 5 ) were exposed to FBA-TPQ (0, 0.1, 0.5 and 1 µM) and incubated for 24 hr prior to analysis. Cells were trypsinized, washed with PBS, and fixed in 1.5 mL of 95% ethanol at 4°C overnight, followed by incubation with RNAse and staining with propidium iodide (Sigma, MO). The DNA content was determined by flow cytometry.
Detection of apoptosis
Cells in early and late stages of apoptosis were detected using an Annexin V-FITC kit from BioVision (Mountain View, CA). In this procedure, 2-3×10 5 cells were exposed to the test compound (0, 0.1, 0.5 and 1 µM) for 24 hr prior to analysis. Cells were collected and washed with serum-free media. Cells were then resuspended in 500 µL of Annexin V binding buffer, followed by addition of 5 µL of Annexin V-FITC and 5 µL of propidium iodide (PI). The samples were incubated in the dark for 5 min at room temperature and analyzed with a Becton Dickinson FACSCalibur instrument (Ex=488 nm; Em=530 nm). Cells positive for Annexin V-FITC alone (early apoptosis) and Annexin V-FITC and PI (late apoptosis) were counted.
Western blot analysis
Cultured cells were exposed to various concentrations of the test compound for 24 hr. Cell lysates were fractionated with identical amounts of protein by SDS-PAGE and transferred to Bio-Rad trans-Blot nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). The nitrocellulose membrane was incubated in blocking buffer (Tris-buffered saline containing 0.1% Tween 20 and 5% nonfat milk) for 1 hr at room temperature, then with the appropriate primary antibody overnight at 4°C or 2 hr at room temperature with gentle shaking. Finally, the membrane was washed three times with washing buffer (Tris-buffered saline containing 0.1% Tween 20) for 15 min, incubated with goat anti-mouse/rabbit IgGhorseradish peroxidase-conjugated antibody (Bio-Rad) for 1 hr at room temperature, and washed again (in triplicate). The proteins of interest were detected by enhanced chemiluminescence reagents from Perkin Elmer LAS, Inc (Boston, MA).
AR and prostate-specific antigen (PSA) expression and PSA promoter-luciferase assay LNCaP cells were seeded on 6-well plates for 48 hr, then exposed to either vehicle, decursin (30 uM), or FBA-TPQ (3 uM) in complete medium containing 10% FBS for 24 hr. Decursin, a natural product known to inhibit the expression of the AR [16] , was used as a reference for comparison. Cell lysates were then examined for AR and PSA expression by Western blotting.
To determine PSA promoter activity, LNCaP cells stably transfected with a luciferase reporter plasmid driven by a 6-kb PSA promoter were seeded into 6-well plates in regular medium. When the cells grew to 40-50% confluence, they were incubated in phenol redfree RPMI 1640 media with 10% charcoal-stripped serum for 24 hr. The cells were treated with 0.5 nM mibolerone combined with FBA-TPQ (0, 0.3, 1.0, or 3.0 µM) for another 24 hr. Conditioned medium was used for the secreted PSA assay as previously described [17] . Cell lysates were processed according to the Promega Luciferase System protocol (Promega Corp., Madison, WI) and analyzed using a luminometer.
Data and statistical analysis
The data were expressed as means and standard deviations, and the significance of differences was analyzed by ANOVA and Student's t-test as appropriate. (Fig. 1b) . Normal IRM90 fetal lung fibroblasts were less sensitive to the inhibitory effects of FBA-TPQ compared to prostate cancer cells. The synthetic marine alkaloid exhibited IC 50 values in the low micromolar range in all tested prostate cancer cell lines (Fig. 1c) .
LNCaP
FBA-TPQ inhibits prostate cancer cell proliferation and induces cell cycle arrest and apoptosis
As the cell growth inhibitory effects of FBA-TPQ observed using the MTT assay provided a general view of cell survival, but did not reflect distinct mechanisms of action, we investigated the effects of FBA-TPQ on cell proliferation, cell cycle progression, and apoptosis. FBA-TPQ inhibited the proliferation of human prostate cancer cells in a dose-dependent manner (Fig. 2a) . PC3 cells were more sensitive than the LNCaP cells, with a significant decrease in proliferation beginning at 0.5 µM (p<0.05), and the PC3 cell proliferation index being decreased by approximately 85% after exposure to 0.75 µM of the compound. The LNCaP proliferation index was also significantly decreased (by ∼30%, p<0.05) at this concentration. As shown in Fig. 2b , the synthetic compound induced significant S phase cell cycle arrest in LNCaP cells and G2/ M arrest in PC3 cells. We also observed that FBA-TPQ induced apoptosis in prostate cancer cells in a concentration-dependent manner (Fig. 2c) . In both human prostate cancer cell lines, a 1.0 µM concentration of FBA-TPQ elicited a significant (p<0.05) increase in apoptosis compared to the control, although the PC3 cells were again more sensitive than the LNCaP cells.
To confirm these effects, the murine TRAMP C1 prostate cancer cell line was also exposed to FBA-TPQ and examined for its effects on proliferation, cell cycle progression and apoptosis. Similar to the human PC3 cells, exposure to 1.0 µM of the compound significantly decreased proliferation, leading to an almost complete inhibition of proliferation (Fig. 3a, p<0.05) . Interestingly, FBA-TPQ induced cell cycle arrest in both the S and G2/M phases of the cell cycle (Fig. 3b) . The murine cells were also highly sensitive to the compound in terms of apoptosis, with the 1 µM concentration increasing apoptosis by more than five-fold (Fig. 3c, p<0.05 ).
FBA-TPQ modulates the expression of apoptosis-related proteins
As our data suggested that the induction of apoptosis is one major mechanism by which FBA-TPQ exerts its anti-cancer effects, we assessed the expression of several apoptosisrelated proteins following FBA-TPQ exposure. Consistent with the Annexin V/flow cytometry experiments, FBA-TPQ activated p53 (in LNCaP cells), down-regulated MDM2, increased Bax, and induced the cleavage of caspases 3, 8, and 9 (Fig. 4) . FBA-TPQ decreases expression of the AR and PSA, secreted PSA levels, and PSA promoter activity Given the differences in the responses of the cells to the compound, and the different levels of androgen sensitivity of the cell lines, we next determined the effect of FBA-TPQ on the expression of the androgen receptor (AR) and PSA in LNCaP cells following exposure to 3 μM FBA-TPQ. We found that this concentration of the compound led to dramatic decreases in both the AR and PSA comparable to those induced by decursin (Fig. 5a) . Additionally, FBA-TPQ significantly decreased the secretion of PSA into the cell culture media (Fig. 5b) , and decreased PSA promoter activity (Fig. 5c ) (p<0.01).
Discussion
Cancer initiation, progression, and metastasis are often the result of myriad genetic mutations. Thus, the genetic and phenotypic heterogeneity of various cancers presents a constant challenge for researchers and physicians. Marinederived compounds have proven to be a rich source of medicinally valuable compounds that are effective against a variety of cancers [10, 18] . However, the limited quantities of these products have often precluded their use in biological investigations. Fortunately, recent technological and methodological advances have improved the organic synthesis of marine natural products and, over the past decade, a number of marine natural products (i.e., bryostatin-1, kahalalide-F, ecteinascidin-743, discodermolide) have entered various phases of advanced pre-clinical and clinical evaluation as potential anti-cancer agents [19, 20] . We recently synthesized several analogs of makaluvamines, a sub-class of marine alkaloids, in an attempt to generate more potent and less toxic compounds. FBA-TPQ, one of these analogs, showed excellent anti-tumor activity in various types of human cancer [15] , prompting the present study. We have made four major observations: 1) FBA-TPQ strongly inhibits the growth of prostate cancer cells, but not normal cells, 2) FBA-TPQ affects cell proliferation and cell cycle progression, 3) the induction of apoptosis appears to be a major mechanism by which the marine alkaloid exerts its anti-cancer effects, however 4) the makaluvamine analog also decreases AR and PSA levels. We have also demonstrated that FBA-TPQ inhibits the growth of both p53 wild-type (LNCaP) and non-functional (PC3, TRAMP C1) cancer cells, as well as androgendependent (LNCaP, TRAMP C1) and -independent (PC3) prostate cancer cells. These findings are important because prostate cancers, particularly advanced cancers, are often androgen refractory and have non-functional p53 [21] . Given the activity of FBA-TPQ against the various models examined here, we believe that the compound will prove to be effective across a broad spectrum of cancers, including advanced prostate cancers.
The regulation of the cell cycle is governed by a complex interaction among numerous proteins, including p53, MDM2, E2F1 and p21 [22] [23] [24] . It is possible that the observed cell cycle arrest is due in part to decreased MDM2 expression. Previous studies have demonstrated that MDM2 inhibition results in increased p53 protein expression and cell cycle arrest, in addition to decreased E2F1 and increased p21 protein expression [25, 26] . These reports are consistent with our findings and provide insight into the molecular targets of this compound and subsequent effects on proliferation and cell cycle progression.
Additionally, since MDM2 inhibition also induces apoptosis, the decrease in expression of this oncogene may also be partly responsible for the pro-apoptotic effects observed in our studies. Consistent with our data, MDM2 inhibition has been shown to result in the upregulation of Bax in LNCaP cells [27] . Moreover, these effects can occur independently of the p53 status of cells [27] .
Our data also indicate that FBA-TPQ decreases secreted PSA levels in a dose-dependent manner. MDM2 was shown to interact with the PSA promoter [28] . We speculate that decreased PSA promoter activity following FBA-TPQ exposure may inhibit the recruitment of MDM2 to the promoter, subsequently decreasing PSA transcription and ultimately the levels of secreted PSA. Thus, it is possible that the effects of FBA-TPQ may be, at least partially, mediated by inhibition of MDM2.
In conclusion, we have demonstrated that FBA-TPQ has potent biological activity against prostate cancers of diverse backgrounds. Although we have identified the induction of apoptosis as a major mechanism of action of the compound, we also observed anti-proliferative and cell-cycle inhibitory effects, as well as a decrease in the AR and PSA. Thus, more studies investigating the translational capacity of this compound in various subtypes of cancer are warranted.
